---
title: "endoxan"
slug: "endoxan"
prefix: "endoxan"
date: "2023-10-06"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[cyclophosphamide]]

# endoxan

- Dosing: 1-5 mg/kg/d PO OR 75-100 mg/m2/d PO Ã— 14 d every 4 wks OR 250-1,800 mg/m2/dose IV Ã— 1-4 d every 3-4 wks OR 40-50 mg/kg IV divided over 2-5 d OR 50-60 mg/kg/d IV Ã— 2-4 doses prior to HSCT. Consider dose adjustment w/ renal & hepatic impairments
- PK/PD: PO bioavailability >75%; prodrug hepatically activated via CYP2B6, 3A4, & 2C9 (metabolites reduce glutathione); renal excretion, T1/2 3-12 h
- AEs: Myelosuppression (DLT; recovery: 7-10 d), hemorrhagic cystitis, nephrotoxicity, SIADH, N/V (high [>1,500 mg/m2], mod. [â‰¤1,500 mg/m2 or PO] emetogenic risk), cardiotoxicity, alopecia, sterility, 2Â° malignancies
- DDI: CYP3A4 inducers (phenobarbital, phenytoin, carbamazepine; â†‘ cyclophosphamide metabolism to active metabolites), CYP3A4 inhibitors (aprepitant, azole antifungals; â†“ cyclophosphamide metabolism)
- Clinical pearls: Properly hydrate pt pre/post-tx. Hemorrhagic cystitis due to accumulation of acrolein in the bladder, can be prevented w/ MESNA (cumulative dose 60-100% of cyclophosphamide dose)
